Science · 1998 · 370 citations · 22 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyNeuropharmacologyPain MedicineAnalgesiaAnalgesic PharmacologyCholinergic PharmacologyNon-opioid AnalgesicsOpioid AnalgesicsPain NeurobiologyAcetylcholine Receptor PharmacologyAnalgesic Drug DevelopmentAnalgesic EffectsNicotinic Receptor PharmacologyNon-opioid AnalgesiaPain PharmacologyReceptor-mediated AnalgesiaSelective Receptor Modulation
Development of analgesic agents for severe pain requires compounds devoid of opioid receptor liabilities. ABT‑594, a potent nAChR ligand (IC50 = 37 pM), produces antinociception comparable to morphine in multiple pain models, its effects are blocked by mecamylamine, and chronic dosing shows no opioid‑like withdrawal or dependence, indicating a non‑opioid analgesic.
Development of analgesic agents for the treatment of severe pain requires the identification of compounds that are devoid of opioid receptor liabilities. A potent (inhibition constant = 37 picomolar) neuronal nicotinic acetylcholine receptor (nAChR) ligand called ABT-594 was developed that has antinociceptive properties equal in efficacy to those of morphine across a series of diverse animal models of acute thermal, persistent chemical, and neuropathic pain states. These effects were blocked by the nAChR antagonist mecamylamine. In contrast to morphine, repeated treatment with ABT-594 did not appear to elicit opioid-like withdrawal or physical dependence. Thus, ABT-594 may be an analgesic that lacks the problems associated with opioid analgesia.
22
Quantitative assessment of tactile allodynia in the rat paw
Sandra R. Chaplan, Flemming W. Bach, J W Pogrel et al. · Journal of Neuroscience Methods · 1994 · 7.9K citations
Zsuzsanna Wiesenfeld‐Hallin, Tomas Hökfelt, Jan M. Lundberg et al. · Neuroscience Letters · 1984 · 573 citations
Epibatidine, a potent analgetic and nicotinic agonist.
Barbara Badio, John W. Daly · Molecular Pharmacology · 1994 · 387 citations